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Abstract
Selective histone deacetylase (HDAC) inhibitors have emerged as a potential anti-latency therapy for persistent human
immunodeficiency virus type 1 (HIV-1) infection. We utilized a combination of small molecule inhibitors and short hairpin
(sh)RNA-mediated gene knockdown strategies to delineate the key HDAC(s) to be targeted for selective induction of latent
HIV-1 expression. Individual depletion of HDAC3 significantly induced expression from the HIV-1 promoter in the 2D10
latency cell line model. However, depletion of HDAC1 or 22 alone or in combination did not significantly induce HIV-1
expression. Co-depletion of HDAC2 and 23 resulted in a significant increase in expression from the HIV-1 promoter.
Furthermore, concurrent knockdown of HDAC1, 22, and 23 resulted in a significant increase in expression from the HIV-1
promoter. Using small molecule HDAC inhibitors of differing selectivity to ablate the residual HDAC activity that remained
after (sh)RNA depletion, the effect of depletion of HDAC3 was further enhanced. Enzymatic inhibition of HDAC3 with the
selective small-molecule inhibitor BRD3308 activated HIV-1 transcription in the 2D10 cell line. Furthermore, ex vivo exposure
to BRD3308 induced outgrowth of HIV-1 from resting CD4+ T cells isolated from antiretroviral-treated, aviremic HIV+
patients. Taken together these findings suggest that HDAC3 is an essential target to disrupt HIV-1 latency, and inhibition of
HDAC2 may also contribute to the effort to purge and eradicate latent HIV-1 infection.
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Introduction
The persistence of latent human immunodeficiency virus type 1
(HIV-1) infection, despite highly effective antiretroviral therapy
(ART), poses a formidable obstacle to eradication of HIV-1. This
reservoir of quiescent HIV-1 proviruses is established early during
acute infection and persists in long-lived resting CD4+ T cells
throughout the life of an infected individual [1–3]. Millions of
people are newly infected with HIV-1 each year, and the health
and economic costs of life-long antiretroviral regimens are a heavy
burden. Therefore, approaches to eradicate HIV-1 are needed [4].
A better understanding of the factors that establish and maintain
HIV-1 latency will allow the design and testing of specific, selective
therapeutic eradication strategies.
Resting CD4+ T cells are resistant to productive HIV-1
infection due to the quiescent phenotype of these cells, which is
characterized by low nuclear levels of the cellular transcription
factors that are required for viral expression [5–8]. Although
evidence exists that HIV-1 occasionally overcomes these barriers
and directly infects resting CD4+ T cells, the latent resting cell
reservoir is primarily thought to be generated when an activated
CD4+ T cell is infected by HIV-1 as it transitions to the long-lived,
resting memory CD4+ T cell state [9,10]. Once an HIV-1
provirus has integrated into the host’s genome, the virus can enter
a quiescent state that is able to persist in the presence of ART.
Furthermore, replication-competent virus can be recovered from
latently infected CD4+ T cells following mitogen stimulation or
exposure to agents such as HDAC inhibitors or protein kinase
agonists [11,12].
During latency, multiple restrictive factors are associated with
the HIV-1 long terminal repeat (LTR) promoter, blocking efficient
transcriptional initiation and mRNA elongation. Among these
factors are HDACs, which are a family of enzymes that regulate
transcription of numerous cellular and viral genes by removing
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acetyl groups from the lysine residues on both histones and non-
histone proteins [13,14]. Deacetylation of histone tails results in
removal of important docking signals that are required for binding
of activating transcription factors. The result is an overall
repressive transcriptional environment. HDACs are divided into
four classes based upon their amino acid sequence, domain
organization, and catalytic dependence on zinc (Class I, II, and
IV) or nicotinamide adenine dinucleotide (NAD+) (Class III) [15].
The class I HDACs include HDAC1, 22, 23, and 28, while
HDAC4, 25, 26, 27, 29, and 210 make up the class II
HDACs, and HDAC11 is the sole member of class IV. Class III
HDACs include sirtuins 1–7, which are NAD+-dependent
deacetylases that are structurally unrelated to the other HDACs.
Class III HDACs have not been associated with maintenance of
HIV-1 latency and are not sensitive to the type of HDAC
inhibitors that induce HIV-1 expression. Therefore, this study
primarily focused on the role that the Class I HDACs play in HIV-
1 expression.
Non-selective and class I-selective HDAC inhibitors are potent
inducers of HIV-1 expression in both cell line models of HIV-1
latency and in ex vivo outgrowth assays using resting CD4+ T cells
from HIV-1-infected individuals [11,16–19]. Furthermore, the
HDACi SAHA upregulates expression of cell-associated HIV-1
RNA in the resting CD4+ T cells of ART-treated, aviremic
patients in vivo [20]. The class I HDACs, HDAC1, 22, and 23,
are recruited to the HIV-1 LTR in cell line models of HIV-1
latency [14,21–24]. These class I HDACs are highly expressed in
the nuclei of resting CD4+ T cells, and sub-class I selective
inhibitors for HDAC1, 22, and 23 are strong inducers of latent
HIV-1 expression in resting CD4+ T cells [21]. However,
inhibitors selective for the class II HDACs do not induce
expression of HIV-1 [21]. HDAC4, 26, or 27 have not been
demonstrated to directly bind to the HIV-1 LTR [21]. Inhibitors
that act only on HDAC1 and 22 but do not inhibit HDAC3 do
not activate latent HIV-1 [21]. This data suggests that HDAC3
enzymatic inhibition is crucial for induction of expression from
quiescent HIV-1 proviruses, but the contributions of HDAC1 and
22 are unclear. Determining the minimal set of HDACs that must
be inhibited to induce latent HIV-1 expression may focus efforts to
identify and develop isoform selective HDAC inhibitors; such
inhibitors might have fewer effects on other cellular genes and less
clinical toxicity.
In an effort to better understand the role of individual class I
HDACs in regulation of HIV-1 transcription, we chose to explore
the impact of single or combination shRNA-mediated depletion of
HDAC1, 22, and 23 on HIV-1 expression in a T cell line model
of latency.
Materials and Methods
Study participants provided written informed consent under a
protocol that was approved by the UNC Biomedical Institutional
Review Board.
Cell lines
2D10 cells were provided by the lab of Jonathan Karn [27]. The
2D10 cells contain a HIV-1 genome with GFP inserted in the
place of nef. J89 and THP89 cells were kindly provided by Dr.
David Levy and contain a full length HIV-1 genome with GFP
inserted between env and nef [25]. J-Lat 6.3 cells were acquired
from the NIH AIDS Reagent Program, Division of AIDS, NIAID,
NIH, from Dr. Eric Verdin and contain a full length HIV-1
genome with a frameshift in env that restricts the insert from
producing env or nef [26]. All cell lines were cultured in RPMI
1640 with 10% FBS, 100 U/ml penicillin (Invitrogen), and
100 mg/ml streptomycin (Invitrogen) [27]. All experiments were
performed using cells that had been passaged fewer than ten times.
Cell cultures were maintained at 37uC under 5% CO2.
Flow cytometry analysis
First, the cells were washed once in PBS and then fixed in PBS
containing 3.2% paraformaldehyde. Flow cytometry was per-
formed using an Attune flow cytometer (Applied Biosystems,
Carlsbad, CA). Analysis of GFP expression was performed using
FlowJo software (Tree Star in.; Ashland, OR), and the statistical
analysis was performed using Graphpad Prism software (La Jolla,
CA). The results are shown as the mean of at least three
independent experiments, and the error bars indicate the standard
error of the mean (SEM).
Transduction of shRNAs
Three million 2D10 cells were aliquoted into fresh media 24 h
prior to transduction. Then, lentiviruses containing shRNAs
specific to the individual HDACs were added to the 2D10 cells,
and 2 mg/ml puromycin was added to the cells 24 h after addition
of lentiviruses to select for cells containing the shRNA expressing
vectors. In experiments that required drugs to be added to the
cells, the drugs were added at 72 h post-transduction. At 96 h
post-transduction, cell samples were collected for flow cytometry
and mRNA expression analysis. Independent transductions were
performed for each experiment. The values shown are the mean of
at least three independent experiments, and the error bars indicate
the standard error of the mean.
HDAC inhibitors
2D10 cells that had been depleted of HDAC1, 22, or 23 with
shRNAs were incubated with the indicated HDAC inhibitors for
18 h. Merck 12 was used at a concentration of 20 mM, Merck 13
was used at a concentration of 200 nM, and SAHA was used at a
concentration of 250 or 500 nM. Mrk12, Mrk13, and SAHA were
generously provided by Merck Research laboratories (West Point,
PA). TSA (T8552, Sigma, St Louis, MO) was used at a suboptimal
concentration of 25 nM, which stimulates detectable GFP in only
5% of 2D10 cells whereas 150 nM stimulates detectable GFP in
over 85% of 2D10 cells. Droxinostat (S1422, Selleckchem.com,
Houston, TX) was used at a concentration of 2 mM. BRD3308
was synthesized at the Broad Institute at .95% purity [28].
2D10 cells were treated with BRD3308 and then washed and
resuspended in fresh media. The cells were then kept in tissue
culture for 24 hours and then collected, fixed, and analyzed using
flow cytometry.
Quantitative viral outgrowth assay (QVOA)
This assay of the frequency of replication-competent HIV-1
within ART-suppressed patient’s resting CD4+ T cells has
previously been described in detail [29]. Study participants
provided written informed consent under a protocol that was
approved by the Institutional Review Board. Briefly, four patients
(Pt 1–4) donated peripheral blood mononuclear cells via leuko-
pheresis, and resting CD4+ T cells were purified using negative
selection. The cells were incubated with antiretroviral drugs to
prevent spread of infection prior to limiting dilution co-culture.
BRD3308 (15 uM) or SAHA (335 nM) was added to aliquots of
resting CD4+ T cells which were then plated in limiting dilution
replicates of 2.5 or 1 million, 0.5 million, and 0.1 million cells and
incubated at 37uC under 5% CO2. Drugs were removed from the
cultures after 24 hours. PBMCs from an uninfected donor were
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added to the cultures twice, and viral outgrowth was measured
using p24 ELISA on the supernatant collected on day 15, and p24-
positive cultures verified on day 19. The results are presented as
the infectious units per million (IUPM) resting CD4+ T, calculated
using a maximum likelihood method. For Patient 3, an IUPM
value from the PHA condition was is not available; therefore, the
IUPM for PHA shown represents the pooled data of three prior
determinations from this patient.
HDAC inhibition assay (microfluidic lab-on-a-chip assay)
All HDACs were purchased from BPS Bioscience. Compounds
were tested in duplicate in a 12-point dose curve with 3-fold serial
dilution starting from 33 mM. Purified HDACs were incubated
with 2 mM carboxyfluorescein (FAM)-labeled acetylated peptide
substrate and test compound for 60 min at room temperature, in
HDAC assay buffer that contained 50 mM HEPES (pH 7.4),
100 mM KCl, 0.01% BSA, and 0.001% Tween-20. Reactions
were terminated by the addition of the known pan HDAC
inhibitor LBH-589 (panobinostat) at a final concentration of
1.5 mM. Substrate and product were separated electrophoretically,
and the fluorescence intensity in the substrate and the product
peaks were determined and analyzed by Labchip EZ Reader. The
reactions were performed in duplicate for each sample. IC50 values
were automatically fitted by Genedata Screener software using 4-
parameter logistic dose response model [30].
RNA extraction and quantitative RT-PCR
RNA was extracted from cells using a QIAgen RNeasy Mini Kit
(Valencia, CA) following the manufacturer’s protocol. DNA was
removed from RNA extracts by DNAse digestion (Promega;
Madison, WI), and cDNA was synthesized using the SuperScript
III First-Strand Synthesis for RT-PCR kit from Invitrogen.
Quantitative PCR was performed on cDNA with a Bio-Rad
CFX96 or CFX384 using QuantiTect Multiplex PCR Mastermix
(QIAgen) and the following primer pairs and 59 FAM-labeled
probes: HDAC1 59 TGAGGACGAAGACGACCCT (forward),
59 CTCACAGGCAATTCGTTTGTC (reverse), and 59
CAAGCGCATCTCGATCTGCTCCTC (probe) [31]; HDAC2
59 CTTTCCTGGCACAGGAGACTT (forward), 59
CTCATTGGAAAATTGACAGCATAGT (reverse), and 59
AGGGATATTGGTGCTGGAAAAGGCAA (probe); and
HDAC3 59 GGTGGTTATACTGTCCGAAATGTT (forward),
59 GCTCCTCACTAATGGCCTCTTC (reverse), and 59 AG-
CAGCGATGTCTCATATGTCCAGCA (probe). Expression of
GFP mRNA from the HIV-1 promoter was measured using the
primers 59 GGAGCGCACCAT CTTCTTCA(forward) and 59
AGGGTGTCGCCCTCGAA reverse along with the 59 FAM
labeled probe 59 CTACAAGACCCGCGCCGAGGTG. A glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH) primer pair
and 59 HEX-labeled probe were included with each reaction for
normalization: 59 GCACCACCAACTGCTTAGCACC (for-
ward), 59 TCTTCTGGGTGGCAGTGATG (reverse), and 59
TCGTGGGAAGGACTCATGACCACAGTCC (probe) [32].
Relative mRNA expression was calculated using the 22DDct
method. The data shown is the mean of at least three independent
experiments, and the error bars represent the standard error of the
mean.
Cell proliferation assays
Cellular proliferation and viability of the 2D10 cells were
determined 96 hours post transduction using the CellTiter-blue
cell viability assay (Promega; Madison, WI) according to the
manufacture’s instructions. The assay was read using a Spectra-
max M3 microplate reader (Molecular devices, Sunnyvale, CA) at
fluorescence 560/590 nM. Viability was calculated as the percent
of viability relative to the scrambled shRNA condition. At least
three independent experiments were performed for each condi-
tion. The values shown in the graphs represent the mean 6 the
SEM.
Statistical analysis
Graphpad Prism software was used to analyze the data. The
Student’s t test was used to compare the mean GFP protein or
mRNA expression in 2D10 cells following transduction with a
scrambled shRNA to cells transduced with HDAC1, 22, and 23
shRNAs. Furthermore, the Student’s t test was used to compare
the mean GFP expression following incubation with HDAC
inhibitors after transduction from at least three independent
experiments. A p-value of less than .05 was considered statistically
significant.
Results
HDAC3 negatively regulates HIV-1 expression in 2D10
cells
To determine the individual contribution of each HDAC to the
maintenance of HIV-1 latency, we first evaluated isozyme-specific
HDAC knockdowns in the 2D10 cell line model of HIV-1 latency.
2D10 cells contain a single, transcriptionally silent HIV-1 genome
that is integrated into the cellular DNA and contains GFP in place
of nef [27]. The 2D10 cell line was clonally selected for a low level
of basal HIV-1 expression, but it is inducible by exposure to
appropriate stimuli, such as tumor necrosis factor alpha (TNF-a)
or HDAC inhibitors [27]. The selection of an appropriate model
system is critical, as although resting CD4+ T cells are inducible
following exposure to HDAC inhibitors in vitro and in vivo
[20,29], model systems in cell lines [33] or even primary cell model
systems [34] are not uniformly responsive to HDAC inhibitors.
2D10 cells were transduced with a scrambled shRNA control
sequence or with shRNAs targeting HDAC1, 22, or 23. The
HDAC mRNA levels following knockdown with the shRNAs were
compared to the expression levels from the scrambled shRNA
control condition 96 h post-transduction. Following transduction,
HDAC1, 22, and 23 mRNA levels were reduced by 70%, 92%,
and 60%, respectively (Fig. 1A). The knockdowns were specific to
the HDAC targeted (Fig. 1A). Furthermore, cellular viability was
not affected by transduction with shRNAs targeting HDAC1, 22,
or 23 when compared to cells that had been transduced with the
scrambled shRNA control 96 h post-transduction (Fig. 1B).
Because transcription from the HIV-1 promoter is induced by
HDAC inhibitors that target the class I HDACs 1, 2, and 3, we
decided to determine if depletion of a single HDAC was sufficient
to induce transcription from the HIV-1 LTR. Therefore, we
assessed the impact of individual HDAC knockdown on HIV-1
expression in 2D10 cells by monitoring GFP protein and mRNA
expression from the HIV-1 LTR for up to 96 hours after
transduction. Depletion of HDAC3 in 2D10 cells led to a
statistically significant increase in the percentage of cells expressing
GFP protein and in mRNA expression from the HIV-1 promoter
when compared to the scrambled shRNA control cells (Fig. 1C).
However, individual HDAC1 or 22 knockdown did not induce a
significant amount of HIV-1 LTR driven GFP protein or mRNA
expression in 2D10 cells. A slight increase in GFP mRNA was
observed following depletion of HDAC2 in the 2D10 cells.
However, this change was not significant. The small change in
mRNA expression that was observed in the cell population was not
sufficient to effect a change in the percentage of cells positive for
GFP protein expression indicating that the change may reflect a
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low level of expression throughout the population rather than a
substantial increase in a subset of cells, which would have resulted
in an increase in the number of GFP positive cells.
Using the same methodology as above, we also depleted the J89,
J-Lat6.3, and THP89 cell line models of latent HIV of the
individual HDACs and did not observe a significant increase in
HIV expression from any of the conditions. This result may be due
to variability between the different cell line models as observed in
previous studies [34,35]. This result further illustrates the
importance of extending and validating findings in patient cells.
Concurrent knockdown of HDAC1 or 22 with HDAC3
does not further increase expression from the HIV-1
promoter compared to depletion of HDAC3 alone
We previously reported that inhibitors selective for HDAC1, 2
2, and 23 are potent inducers of HIV-1 expression [21].
Therefore, to determine if dual inhibition of a pair of these
HDACs increased the induction of HIV-1 expression, compared
to inhibition of HDAC3 alone, we evaluated the effects of
combined shRNA-mediated HDAC knockdown on latent HIV-1
expression in 2D10 cells. The targeted HDAC mRNA expression
levels following combination knockdowns were similar to those
obtained following individual knockdowns at 96 hours after
transduction (compare Figs. 1A and 2A). Cell viability was not
affected at 96 hours following combination HDAC depletion
when compared to the scrambled shRNA control (Fig. 2B).
Depletion of HDAC2 and 23 resulted in a significant increase
in the percent of cells expressing HIV-1 LTR driven GFP protein
and in HIV-1 driven GFP mRNA expression over the cells that
were transduced with the scrambled shRNA (Fig. 2C). However,
this increase was not significantly different from the increase
observed following depletion of HDAC3 alone. The combined
knockdown of HDAC1 and 23 resulted in a modest, but not
significant, increase in the percent of cells expressing GFP protein
and HIV-1 driven mRNA expression over cells that were
transduced with the scrambled control (Fig. 2C). Similar to single
knockdown of HDAC1 or 22, we did not observe an induction of
GFP protein or mRNA expression when HDAC1 and 22 were
inhibited together. Therefore, depletion of HDAC1 or 22 in
combination with HDAC3 does not enhance the inducing effects
observed following depletion of HDAC3 alone.
Combined knockdown of HDAC1, 22, and 23 induces
modest expression from the HIV-1 LTR
As we have previously observed induction of HIV-1 expression
in 2D10 cells with inhibitors that selectively target HDAC1, 22,
and 23, it is possible that optimal induction of HIV-1 may require
simultaneous inhibition of all three HDACs [21]. Thus, we tested
the effects of combined knockdown of HDAC1, 22, and 23 on
HIV-1 expression using the shRNAs described above. HDAC
mRNA levels were reduced at 96 hours after transduction with
HDAC shRNAs when compared to transduction with the
scrambled shRNA control (Fig. 3A). Concurrent knockdown of
HDAC1, 22, and 23 by simultaneously transducing the three
individual shRNAs that were used in the single knockdowns did
not affect cellular viability at 96 h post-transduction when
compared to the scrambled shRNA control (Fig. 3B). A significant
increase in the percent of cells expressing GFP protein and in
mRNA expression from the HIV-1 promoter was observed in cells
depleted of HDAC1, 22, and 23 as compared to the scrambled
shRNA control (Fig. 3C). However, as with the dual combination
knockdowns, the amount of expression induced by all three
HDACs was not significantly more than that observed following
depletion of HDAC3 alone. Therefore, the significant increase
observed following depletion of all three HDACs over the
scrambled shRNA control condition is likely due to the effects of
HDAC3 depletion.
Enzymatic inhibition of HDACs potentiates the effects of
HDAC3 depletion
Because the depletion of the HDACs was not complete when
using the shRNAs to deplete the HDAC protein, we next used
both selective and global HDAC inhibitors to enzymatically
inhibit the remaining HDAC activity following targeted shRNA-
Figure 1. Depletion of HDAC3 significantly increases expression from the HIV-1 promoter. A. Expression of the indicated HDAC mRNAs
following shRNA mediated depletion of HDAC1, 22, or 23 in 2D10 cells. Depletion of HDAC1, 22, or 23 was significant and specific for the targeted
HDAC. B. Cell proliferation was not significantly affected following depletion of HDAC1, 22, or 23 in 2D10 cells. C. The percentage of 2D10 cells
expressing GFP protein from the HIV-1 promoter following depletion significantly increased following depletion of HDAC3 in comparison to control
cells transduced with the scrambled shRNA, but not following depletion of HDAC1 or 22. The same effect was seen when GFP mRNA expression was
directly measured. Expression was not significantly altered from baseline following transduction with non-specific shRNA. (*p,0.05).
doi:10.1371/journal.pone.0102684.g001
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mediated depletion. HIV-1 LTR expression in the presence of the
vehicle (DMSO) used for these inhibitors is low, and the effect of
HDAC3 depletion was significant (Fig. 4A). In the presence of
selective inhibition of HDAC1 and 22 with 20 mM of the drug
Mrk12 [21], depletion of HDAC1 did not significantly affect the
percentage of cells expressing GFP from the HIV-1 promoter
Figure 2. Co-depletion of HDAC2 and HDAC3 significantly increases expression from the HIV-1 promoter. A. Expression of the
indicated HDAC mRNAs following shRNA mediated depletion of HDAC1 and 22, HDAC1 and 23, or HDAC2 and 23. The depletion was significant
and specific for the targeted HDACs. B. Cell proliferation and viability of 2D10 cells that were transduced with shRNAs targeting HDAC1 and 22,
HDAC1 and 23, or HDAC2 and 23. No significant changes in cell proliferation and viability were observed following co- depletion of these HDACs as
compared to cells that were transduced with the scrambled shRNA control. C. Expression of GFP from the HIV-1 promoter following depletion of
HDAC2 and 23 increased compared to the control cells transduced with a scrambled shRNA. However, depletion of HDAC1 and 22 or HDAC1 and 2
3 did not have a significant effect on GFP expression. This same result was seen when GFP mRNA expression was directly measured. Expression was
not significantly altered from baseline following transduction with non-specific shRNA. (*p,0.05).
doi:10.1371/journal.pone.0102684.g002
Figure 3. Depletion of HDAC1, 22, and 23 significantly increases expression from the HIV-1 promoter. A. Fold change of HDAC1, 22,
and 23 mRNA expression as compared to 2D10 cells transduced with the scrambled shRNA control. A significant reduction in the mRNA expression
of all three HDACs was observed. B. Cell viability and proliferation as a percentage of the 2D10 cells transduced with the scrambled shRNA control.
Depletion of HDAC1, 22, and 23 did not significantly affect cell viability and proliferation. C. A significant increase in the percentage of cells
expressing GFP protein from the HIV-1 promoter was observed following depletion of HDAC1, 22, and 23. Furthermore, a significant increase in
expression of GFP mRNA from the HIV-1 promoter was observed following depletion of HDAC1, 22, and 23. (*p,0.05).
doi:10.1371/journal.pone.0102684.g003
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(Fig. 4B). When Mrk12 was added to cells that were depleted of
HDAC2 there was a modest increase in the percentage of cells
expressing GFP from the HIV-1 promoter over cells treated with
the scrambled shRNA control and Mrk12. However, when Mrk12
was added to cells that were depleted of HDAC3 a 3-fold increase
in the percentage of cells expressing GFP from the HIV-1
promoter was observed over cells treated with the scrambled
shRNA control and Mrk12 (Fig. 4B). Furthermore, 200 nM of
Mrk13 an inhibitor selective for HDAC1, 22, and 23 [21]
activated GFP expression by itself, but a further increase in the
percent of cells expressing GFP from the HIV-1 promoter was
seen in cells that were depleted of HDAC2 and 23 but not
HDAC1 or transduced with the scrambled shRNA control
(Fig. 4C).
Next, we used the HDAC inhibitor suberoylanilide hydroxamic
acid (SAHA or vorinostat), which is selective for HDAC1, 22, 23,
and 26 to partially (at 250 nM) or fully (at 500 nM) inhibit
HDAC1, 22, and 23. Similar to the results found with Mrk12
and 13, the suboptimal concentration of SAHA induced a
significant increase in the percentage of GFP expressing cells in
cells that were depleted of HDAC2 and 23 but not HDAC1
(Fig. 4D). When the maximal concentration of SAHA was
combined with depletion of HDAC1, 22, or 23, we observed a
significant increase in the percent of cells expressing GFP from the
HIV-1 promoter in the cells depleted of HDAC3, but not HDAC1
or 22, over 2D10 cells treated with the scrambled shRNA control
and SAHA (Fig. 4E). Furthermore, inhibition with a suboptimal
concentration (25 nM) of the non-selective HDAC inhibitor TSA
also significantly enhanced the effect of HDAC3 depletion
(Fig. 4F). As the percentage of cells expressing GFP from the
HIV-1 promoter increased somewhat in three of the conditions in
cells depleted of HDAC2 (Fig. 4B–D), we cannot rule out a
contributory role for HDAC2 in repression of HIV-1 transcrip-
tion. However, expression from the HIV-1 promoter increased in
combination with all of the tested drugs in cells depleted of
HDAC3, indicating a consistent role for HDAC3 in mediating
HIV-1 LTR repression.
To determine whether further inhibition of HDAC3 without
inhibition of HDAC1 or 22 was sufficient to induce transcription
from the HIV-1 LTR we used Droxinostat, an HDAC inhibitor
that selectively inhibits HDAC3, 26, and 28 [36]. Droxinostat
(2 mM) was used to inhibit HDAC3 activity after depletion of
HDAC1, 22, or 23. Again, depletion of HDAC1 or 22 with
inhibition of HDAC3 did not increase the percent of cells with
LTR driven GFP protein expression observed over Droxinostat
treatment of the cells transduced with the scrambled shRNA
(Fig. 4G). However, inhibiting the enzymatic activity of the
remaining HDAC3 enzyme with Droxinostat following HDAC3
depletion induced a significant increase in the percent of cells
expressing GFP protein from the HIV-1 LTR compared to cells
that were transduced with the scrambled control and treated with
Droxinostat (Fig. 4G). Altogether, these results support the above
results, indicating that inhibition of HDAC3 is key for reactivation
of latent HIV-1, and suggest a weaker, contributory role for
HDAC2.
JQ1 enhances HIV-1 transcription in HDAC3 depleted
cells
It is not clear that HDAC inhibitors can induce a sufficient level
HIV-1 expression in vivo to allow clearance of latent infection,
and so combinatorial approaches to disrupt latency have been
proposed [18,19]. JQ1 is an inhibitor of bromodomain proteins
that is capable of inducing expression of quiescent HIV-1 proviral
promoters [35,37]. We sought to determine whether JQ1 could
also enhance the effect of HDAC3 depletion. To this end, cells
that had been depleted of HDAC1, 22, or 23 were treated with
50 nM JQ1 overnight. Similar to the results from the HDAC
inhibitor studies, we found that LTR expression induced by JQ1
was enhanced by depletion of HDAC3, but not HDAC1 or 22
(Fig. 5).
HDAC3 selective inhibition induces expression of HIV
BRD3308 is a derivative of the ortho-aminoanilide HDAC
inhibitor CI-994 and was developed to be highly selective for
inhibition of HDAC3 with an IC50 value that is 23-fold lower for
HDAC3 than for HDAC1 or 22 (Table 1). To determine whether
enzymatic inhibition of HDAC3 was sufficient to induce
transcription of HIV-1 in a cell line model of HIV, 2D10 cells
were exposed to either 5 mM, 10 mM, 15 mM, or 30 mM of
BRD3308 for 6, 12, 18, or 24 hours, and LTR-driven GFP
expression was monitored by flow cytometry. By 12 hours at
concentrations of 10 mM and greater an increase in HIV-1
expression was observed in the 2D10 cell line (Fig. 6).
Inhibition of HDAC3 induces outgrowth of HIV-1 from
patient cells
Given the limitation of clonal cell line models of HIV-1 latency,
and the recently recognized limitations of polyclonal primary cell
models of HIV-1 latency [34], we wished to directly test the role of
HDAC 3 inhibition through the use of the gold-standard
quantitative viral outgrowth assay using resting CD4+T cells
isolated from aviremic patients on ART [1,11,21,29]. Attempts to
accomplish this by transduction of patient’s cells with siRNAs
targeting HDACs 1–3 were not inconsistent with a role for
HDAC3, and a contributory role for HDAC2, in the maintenance
of HIV-1 latency. However, the studies were limited by
incomplete HDAC knockdown and upregulation of CD69 on
resting CD4+ T cells induced by the nucleofection procedure, and
limited induction of viral outgrowth by knockdown of HDAC2 or
23 (data not shown).
We therefore compared the induction of viral outgrowth
following the exposure of patients’ resting CD4+ T cells to the
HDAC3 selective inhibitor BRD3308 or the Class I HDAC
inhibitor SAHA. Cells from four patients (Pt 1, Pt 2, Pt 3, and Pt 4)
were exposed to 15 mM of BRD3308 or 335 nM of SAHA
overnight. In all four patients, 15 mM of BRD3308 induced a
similar or greater amount of viral outgrowth as exposure to SAHA
(Fig. 7A). Furthermore, PBMCs exposed to 5 mM, 10 mM, 15 mM,
or 30 mM BRD3308 for 24 hours did not show a significant
decrease in viability when compared to PBMCs exposed to the
vehicle control (0.015% DMSO) (Fig. 7B). Additionally, the
percent of cells expressing the T cell activation markers CD69,
CD25, and HLA-DR did not increase following treatment with
15 mM of BRD3308 (data not shown). This data demonstrates that
exposure to an HDAC3 selective inhibitor allows the recovery of
latent HIV-1 from patient cells at a similar frequency as the
selective Class I HDAC inhibitor SAHA without decreasing cell
viability or inducing cell activation, in contrast to the absence of
viral induction observed following exposure to an inhibitor specific
for HDAC1 and 22 [38].
Discussion
Selective inhibitors that target HDAC1, 22, and 23, but not
those that only inhibit HDAC1 and 22, are potent inducers of
HIV-1 transcription [18,21]. In an effort to determine the minimal
HDAC-isoform(s) inhibition that is necessary for optimal induction
of latent HIV-1, we employed an shRNA-mediated strategy to
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Figure 4. Chemical inhibition of HDACs following depletion of HDAC3 significantly increases expression from the HIV-1 promoter.
A. 2D10 cell that had been depleted of HDAC1, 22, or 23 or had been infected with the scrambled control lentivirus were exposed to 0.015% DMSO
as the vehicle control for 24 hours. B. Chemical inhibition of HDAC1 and 22 using Mrk 12 (20 mM) does not result in a significant increase in the
percentage of 2D10 cells expressing GFP following depletion of HDAC1 or 22. However, similar to depletion of HDAC3 alone, a significant increase in
the percent of cells expressing GFP was observed when Mrk 12 was added to cells depleted of HDAC3. C. Chemical inhibition of HDAC1, 22 and 23
with Mrk 13 (200 nM) resulted in a significant increase in the percent of GFP positive 2D10 cells in cells depleted of HDAC2 or 23, but not HDAC1. D.
A submaximal (250 nM) concentration of SAHA resulted in a significant increase in the percent of cells expressing GFP following depletion of HDAC2
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deplete individual and combinations of the class I HDACs,
HDAC1, 22, and 23, in the 2D10 T cell line model of quiescent
HIV-1. We found that isolated depletion of HDAC3 expression
resulted in a statistically significant induction of LTR driven GFP
protein expression in 2D10 cells (Fig. 1D). Furthermore, inhibition
of HDAC3 in combination with HDAC1, 22, or both HDAC1
and 22 induced a significant increase in expression from the HIV-
1 promoter, but not significantly more than depletion of HDAC3
alone. These findings support our previous studies on the effects of
selective HDAC inhibitors and further define the minimal HDAC
inhibition that is required for reactivation of latent HIV-1 [21].
It worth noting that the rate of knockdown achieved by the
individual HDAC shRNAs in this study ranged from 48% to 95%
(Figs. 1A, 2A, 3A, and 5A); thus, there was not a complete
elimination of any of the HDACs targeted. Because HDAC1, 22,
and 23 are all known to associate with the HIV-1 LTR [21], it is
possible that some combination of these HDACs may remain to
regulate the viral promoter following knockdown with shRNA.
Furthermore, transduction with shRNAs results in a slow depletion
of protein expression. In contrast, chemical HDAC enzymatic
inhibition occurs rapidly and persists until the drug is cleared.
To address these concerns, we depleted 2D10 cells of HDAC1,
22, or 23 and used small molecules inhibitors to block the
remaining HDAC activity. We found that in cells depleted of
HDAC3, chemical inhibition of the remaining HDAC activity
enhanced expression of GFP from the HIV-1 LTR for all of the
drugs studied. Furthermore, a modest increase in expression from
the HIV-1 LTR was also observed in cells that were depleted of
HDAC2 when cells were exposed to the HDAC inhibitors
MRK12 and MRK13, and to SAHA, indicating that HDAC2
may also have a contributory role in the maintenance of HIV-1
latency. Importantly, no change in expression from the HIV-1
promoter was observed in cells depleted of HDAC1. Altogether,
the consistent increase in expression from the HIV-1 promoter
that was observed in cells depleted of HDAC3 indicates that
HDAC3 is a key factor in repression of HIV-1 expression.
Keedy et al. used siRNAs to deplete the HeLa P4/R5 cell line
model of latent HIV-1 of HDAC1, 22, or 23 and observed that
depletion of HDAC2 alone induced LacZ expression from the
HIV-1 promoter and that depletion of HDAC3, but not HDAC2,
in conjunction with 1 uM of TSA significantly induced expression
over treatment with TSA alone. It is interesting that no increase in
HIV-1 driven LacZ expression was observed following HDAC3
depletion alone in this study, which is in contrast to the results
from this study. This discrepancy may be attributable to
differences in the level of knockdown, differences between the
models or with the different methodologies that were used. HeLa
cells are an epithelial cell line that is physiologically different from
latently infected CD4+ T cells. Jurkat cells, such as the 2D10 cells
used in this study, are CD4+ lymphoid cells more closely related to
CD4+ T cells most commonly infected by HIV-1 in vivo.
However, although these two cell lines and the studies conducted
in them are very different, it is interesting that in both studies
HDAC2 and 23, but not HDAC1, were found to be important in
expression from the HIV-1 promoter. In another study, Huber et
al. depleted, J89GFP cells (Jurkat cell line that contains GFP under
the control of the HIV-1 promoter) of HDAC1, 22, or both and
found no difference in the percent of GFP positive cells compared
to the control siRNA condition, which is similar to the results
found in this study when HDAC1 or 22 were depleted
individually or in combination. The work in this study further
extends the finding from these previous studies to an additional cell
line and provides additional evidence that targeting HDAC3 and
possibly HDAC2, but not HDAC1, can be used to induce
expression from the HIV-1 promoter.
Huber et al. demonstrated that Droxinostat, an inhibitor
reported to target HDAC3, 26, and 28, activated transcription
from a cell model of HIV-1 latency [36]. However, as other data
finds that the IC50s of Droxinostat are 16.9 mM (HDAC3),
2.47 mM (HDAC 6), and 1.46 mM (HDAC 8) [39], the primacy of
HDAC3 inhibition was unclear. In this study, treating 2D10 cells
depleted of HDAC3 with 2 mM of Droxinostat resulted in a
significant increase in GFP expression from the HIV-1 LTR over
cells transduced with the scrambled shRNA and treated with
Droxinostat (Fig. 4E). A significant increase in LTR-driven GFP
expression was detected with 2 mM of Droxinostat, which is the
IC50 of this drug for HDAC3 and is 2.5 fold below the IC50 value
for HDAC8 and 30 fold below the IC50 for HDAC1 [36]. These
results further support the above results indicating that targeting
HDAC3 alone may be sufficient to induce transcription from
quiescent HIV-1 proviruses.
JQ1 is an inhibitor of Brd4 that has been demonstrated to be
able to induce HIV-1 transcription [35,37]. In this study, it was
demonstrated that treating HDAC3 depleted 2D10 cells with JQ1
significantly increased expression from the HIV-1 promoter over
the amount of expression observed following HDAC3 depletion or
treatment with JQ1 only. Therefore, selective inhibition of
HDAC3 may have potential for use in combination therapies
with Brd4 inhibitors like JQ1.
and 23. E. A maximal concentration of SAHA (500 nM) resulted in a significant increase in the percent of cells expressing GFP in cells depleted of
HDAC3. However, in D. or E. depletion of HDAC1 did not increase the percent of cells expressing GFP. F. Chemical inhibition of HDACs with the non-
selective inhibitor TSA (25 nM) resulted in a significant increase in the percent of GFP expressing 2D10 cells in cells depleted of HDAC3, but not
HDAC1 or HDAC2. G. Chemical inhibition of HDAC3, 26, and 28 with the selective HDAC inhibitor Droxinostat (2 mM) resulted in a significant
increase in the percent of 2D10 cells expressing GFP in cells that had been depleted of HDAC3 but not HDAC1 or 22. (*p,0.05).
doi:10.1371/journal.pone.0102684.g004
Figure 5. JQ1 enhances the effects of HDAC3 depletion. A
significant increase in GFP protein expression from the HIV-1 promoter
was observed in 2D10 cells that had been depleted of HDAC3 and had
been treated with JQ1 (50 nM) for 24 hours over cells that were
transduced with the scrambled shRNA control and treated with JQ1.
However, no effect was observed in cells depleted of HDAC1 or HDAC2.
(*p,0.05).
doi:10.1371/journal.pone.0102684.g005
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To reinforce the role of HDAC3, we next tested the effect of
BRD3308, which is an HDAC3 selective inhibitor. In addition to
inducing expression in the 2D10 cell line, BRD3308 is able to
induce outgrowth of HIV-1 from latently infected patient cells ex
vivo comparably to the HDAC inhibitor SAHA (Fig. 7A). These
results indicate that more selective inhibition of HDAC3 may be
sufficient to reverse latency.
HDAC1, 22, and 23 have been demonstrated to physically
associate with the HIV-1 LTR [40], and inhibition of these
HDACs with small molecule HDAC inhibitors is associated with
increased acetylation of histones at the HIV-1 LTR [41].
Therefore, it is interesting that depletion of HDAC3, but not
HDAC1 or 22, activates transcription from the HIV-1 promoter.
HDAC3 is unique from HDAC1 and 22 in several aspects, which
may explain its unique role in the maintenance of HIV-1 latency.
HDAC1 and 22 are 85% similar to each other; however, HDAC3
is only 53% and 52% similar to HDAC1 and 22, respectively.
Furthermore, HDAC3 contains a unique amino acid sequence at
its carboxy terminus that is not found in HDAC1 or 22 [42]. In
addition to its nuclear localization signal, HDAC3 contains
cytoplasmic and cell membrane-targeting regions that are not
found in HDAC1 and 22 [42]. HDAC2 and 23 are located in
both the cytoplasm and nucleus in resting and activated CD4+ T
cells from HIV-1 infected aviremic patients [40]. In contrast,
HDAC1 is only found in the nucleus [40]. In addition to affecting
localization, these sequence differences may also account for
HDAC3’s unique complex association. HDAC3 is associated with
the NCoR and SMRT complexes, while HDAC1 and 22 are
associated with the CoREST, NuRD, REST, and Sin complexes
[43,44]. NCoR has been demonstrated to bind to the HIV-1 LTR
in monocyte-derived macrophages [45]. Furthermore, we find
NCoR at the HIV-1 LTR in the J89 Jurkat cell line model of HIV-
1 latency (Barton and Margolis, data not shown). The association
of NCoR with the HIV-1 promoter indicates that HDAC3 may be
mediating its effects through the NCoR complex. Therefore, the
differences in effects observed following individual depletion of
HDAC1, 22, and 23 may be due to the differences in complex
association, sequence diversity or expression.
Although HDAC3 depletion and inhibition resulted in consis-
tent activation of quiescent HIV, a putative contribution of
HDAC2 was observed when it was depleted in conjunction with
HDAC3. Of the HDACs that are found at the HIV-1 promoter,
HDAC1 and 23 have the most highly expressed mRNAs and are




























































































































































































































Figure 6. An HDAC3 selective inhibitor induces HIV-1 expres-
sion from 2D10 cells. 2D10 cells were treated with BRD3308 at the
indicated concentration for 6 hours, 12 hours, 18 hours, or 24 hours
and collected for analysis at 24 hours. The percent of 2D10 cells
expressing GFP was measured using flow cytometry. HIV-1 expression
was observed with 10 mM of BRD3308 and higher after 12 hours of
treatment.
doi:10.1371/journal.pone.0102684.g006
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respectively [40]. Therefore, the minimal role of HDAC2 in
reactivation of latent HIV-1 may be associated with its low level of
expression relative to the other two HDACs.
We sought to determine the minimal set of HDAC-isoform(s)
whose inhibition is necessary to induce latent HIV-1 expression.
Selective HDAC inhibitors targeting HDAC1 and 22 were not
sufficient to induce latent HIV-1 expression [21]. Furthermore,
selective chemical inhibition of HDAC3 was sufficient to induce
transcription in both the cell line model of HIV-1 latency and ex
vivo from latently infected patient cells. In this study, selective
targeting of HDAC3 was demonstrated to be sufficient to induce
expression from the HIV-1 promoter.
Selective HDAC inhibitors that target a limited number of the
class I HDACs have potential as anti-latency therapies in HIV-1
infection with fewer host toxicities as selective inhibitors may have
reduced off-target effects. We previously demonstrated that
inhibitors that selectively target HDAC1, 22, and 23—but not
HDAC1 and 22 alone—are potent inducers of latent HIV-1 [21].
In this study, we evaluated whether a more selective induction of
HIV-1 could be achieved using a shRNA-mediated strategy of
HDAC knockdown in the 2D10 cell line model of HIV latency.
Our results indicate that depletion or inhibition of HDAC3
significantly induces expression from the HIV-1 promoter.
However, a potential contributory role of HDAC2 cannot be
ruled out, and it appears that molecules that inhibit HDAC3 (and
perhaps HDAC2) but avoid HDAC1 inhibition might mediate
maximal HIV-1 LTR induction. Overall, we conclude that further
studies are needed to optimally design HDAC inhibitors for use in
anti-latency strategies and to determine if it is clinically preferable
to specifically target HDAC3 in the hope of avoiding clinical
toxicities or to target both HDAC2 and 23 in the hope of
optimally inducing a broad array of latent HIV-1 genomes.
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